DepoTech commences Phase III trials of DTC 101 in Canada.LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BUSINESS WIRE)--Nov. 3, 1994--DepoTech Corp. Thursday announced the start of multi-center Canadian Phase III clinical trials for DTC DTC See: Depository Transfer Check DTC See: Depository Trust Company DTC See Depository Trust Company (DTC). 101, an anti-cancer therapeutic, in patients with neoplastic meningitis The infiltration of the subarachnoid space with cancer cells. The cancer cells can be metastatic or from a primary brain tumor like medulloblastoma. . Neoplastic meningitis is a complication of many forms of cancer that oo the cerebrospinal fluid cerebrospinal fluid (CSF) Clear, colourless liquid that surrounds the brain and spinal cord and fills the spaces in them. It helps support the brain, acts as a lubricant, maintains pressure in the skull, and cushions shocks. (CSF Cerebrospinal Fluid (CSF) Analysis Definition Cerebrospinal fluid (CSF) analysis is a laboratory test to examine a sample of the fluid surrounding the brain and spinal cord. ). The primary endpoints of the studies are clearing of cancer cells from the CSF; time to complete response; duration of response; and time to relapse. DTC 101 is an injectable, sustained-release formulation of the chemotherapeutic agent chemotherapeutic agent An agent used to treat CA, administered in 'regimens'-one or more 'cycles' that combine 3 or more agents over wks; CAs are toxic to any cell with a high rate of proliferation–the CA itself, the GI tract–causing N&V, ara-C (cytarabine) that consists of the drug encapsulated in DepoFoam, DepoTech's novel lipid-based drug delivery system. DepoFoam-encapsulation provides a mechanism for sustained-release of drug over a period of weeks. DepoTech is developing DTC 101 in collaboration with Chiron Therapeutics, a business unit of Chiron Corp., which has exclusive marketing rights to the drug in the U.S., Canada and Europe. "In addition to providing information for Canadian approval of DTC 101, these new trials will support our data acquisition for the U.S. New Drug Application," commented Edward L. Erickson, president and chief executive officer of DepoTech. DepoTech Corp. is a drug delivery company engaged in the development and manufacture of sustained-release therapeutic products based on DepoFoam, a proprietary injectable depot drug delivery technology. CONTACT: DepoTech Corp. Edward L. Erickson, 619/625-2424 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion